Baiyunshan (00874.HK)'s subsidiary Guangzhou Medicine sells the first new underlying assets to Xingzheng Asset Management and receives a purchase price of 0.524 billion yuan.

Gelonghui reported on November 28 that baiyunshan ph (00874.HK) announced that on November 28, 2024, the company's non-wholly-owned subsidiary Guangzhou Medicine signed a "New Basic Asset Delivery Confirmation Letter" with Xingzheng Asset Management according to the Basic Asset Sale Agreement (Phase IV), confirming the sale of the first newly added basic asset to Xingzheng Asset Management and receiving a purchase price of 524,000,713.50 yuan.

Gelonghui Finance04:13 ET

Baiyunshan Pharma's Unit Gets Nod to Make Changes to Selaginella Jiangnanensis Tablets

MT Newswires23:23 ET

Baiyunshan Pharma Gets Nod to Market Anti-Tumor Drug

MT Newswires23:11 ET

Baiyunshan (600332.SH): Cefdinir granules have received a pharmaceutical registration certificate.

On November 25, Gelonghui reported that baiyunshan ph (600332.SH) announced that its holding subsidiary, Guangzhou baiyunshan ph Tianxin Pharmaceutical Co., Ltd. (referred to as 'Tianxin Pharmaceutical'), received the pharmaceutical registration certificate approved and issued by the National Medical Products Administration for Cefdinir Granules (50mg). Cefdinir Granules belong to the third generation of cephalosporin antibiotics, which mainly exert their bactericidal effect by inhibiting the synthesis of bacterial cell walls, making it a broad-spectrum antibiotic that was approved for market launch in 2002 in china. It is suitable for the treatment of Staphylococcus, Streptococcus, Pneumococcus, Streptococcus dysgalactiae, and Propionibacterium that are sensitive to Cefdinir.

Gelonghui FinanceNov 25 04:10 ET

Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt Responsibly

Simply Wall StNov 22 20:24 ET

China Approves Baiyunshan Pharma Unit's Supplementary Application for Traditional Chinese Drug

MT NewswiresNov 22 03:43 ET